Rats were injected with colchicine and the secretion of triglycerides into the serum was studied for 90 min after injection of [14C]palmitic acid and Triton WR 1339. The release of labeled and chemically determined triglyceride was reduced to about 20-30% of control values. The effect of colchicine on serum triglyceride levels was not dependent on the presence of Triton and was similar in males and females and in fed and fasted rats. The effect was dose dependent and was reversible 6-7 h after injection of 0.05 mg/100 g body weight. Colchicine inhibited also the release of labeled proteins into the serum but did not affect the amount of [3H]leucine incorporated into liver proteins. Within 4 h of colchicine treatment there was an 80% fall in serum very low density lipoproteins (VLDL), a 30% fall in serum high density lipoproteins (HDL), and no change in the d > 1.21 protein level, but reduction in the appearance of labeled proteins was encountered in all serum fractions. Colchicine had no effect on the rate of bile flow and on the secretion of phospholipids and cholesterol into the bile. In the hepatocyte there was accumulation of Golgi-derived secretory vesicles, containing nascent VLDL particles; these vesicles were seen also in the vicinity of the sinusoidal cell surface, but the space of Disse contained few or no VLDL particles. There was an apparent reduction in microtubules and some increase in microfilaments. It is suggested that microtubules affect the secretion of lipoproteins and proteins into the serum by maintaining the organization of the plasma membrane required for its fusion with secretory vesicles. The lack of effect of colchicine on biliary lipid secretion indicates that the latter is not dependent on vesicular transport.

Current methods for measuring the cell kinetics of human tumours are made and interpreted within the context of a simplistic two compartment model for cell proliferation, consisting of cells that are cycling and those that are not. It is now recognized that the non-cycling compartment of many tumours is heterogeneous, composed of non-reproductive end-stage cells and reproductive cells that are dormant/quiescent. We have developed an in vitro analysis that distinguishes for the first time quiescent reproductive cells from non-reproductive end-stage cells and have integrated this analysis with monolayer clonogenic and suicide assays to simultaneously quantitate the duration of the cell cycle and reproductive cells that are: cycling, quiescent, clonogenic, and non-reproductive end-stage cells. We have defined a new parameter, the Cycling Reproductive Fraction (CRF), which is the cycling cell population referenced specifically to the reproductive cell population. Measurements of CRF from 72 tumour biopsies and from 5 normal foreskins showed that CRF approached 100% in some tumours; however, CRF showed near normal values (< 1%) in others suggesting that cell cycle control may be maintained in some tumours. Because of CRF's improved specificity, we believe that CRF may enhance classification, prognostication, and the optimization and prediction of response to chemotherapy.

No abstract

Considering that tumors are maintained by clonogenic cells, and that the primary target in the therapy of cancer is the clonogenic cell, the density of clonogens in a tumor could become an important parameter in quantitating the response to therapy. Indirect methods for determining the density of clonogenic cells in human tumors based on the response of tumors to radiation suggest there are circa 1 X 10(5) clonogens per gram with a large range. Direct methods, based on the measurement of cloning efficiency of enzymatically disaggregated biopsies of human tumors in soft agar, suggest a clonogen density of approximately 1,500 clonogens per gram. As this value is inconsistent with the prior data, we chose to determine the density of clonogenic cells in human tumors by assaying the enzyme digest of biopsies of human tumors for clonogenic cells using an enriched monolayer clonogenic assay. We determined the average clonogen density to be 1.12 x 10(5) clonogens per gram with a large range. The agreement with the indirect method suggests that the enriched monolayer clonogenic assay supports the proliferation of the cell population responsible for maintaining the tumor.